NV-RIMINI-STREET,-INC.
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, has appointed Eric Helmer as its chief technology officer (CTO) and announced the establishment of the Office of the Chief Technology Officer (OCTO). As CTO at Rimini Street, Helmer is charged with helping prospects and clients design and deploy innovative solutions and roadmaps to achieve strategic IT, operational and financial goals across various enterprise applications and technology products from proprietary vendors such as Oracle, SAP, IBM, Salesforce and Microsoft and open source products such as MySQL, MariaDB, PostgreSQL and MongoDB database platforms. Mr. Helmer reports to Sebastian Grady , president at Rimini Street.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005974/en/
Rimini Street’s OCTO was created to accelerate innovation and provide prospects and clients with unique solutions and roadmaps that maximize the effectiveness of their mission-critical enterprise software systems. It was also created to help prospects and clients build a software and technology landscape that is future-proofed against a variety of technology changes and business needs, is innovation-ready to meet the needs of the enterprise today and tomorrow and is scalable and highly secure.
The OCTO will provide comprehensive, strategic, technical, functional and feature-release road-mapping advisory services and collaborate with prospects and clients to define a vision for what is next and possible in leveraging their core, mission-critical enterprise IT systems.
CTO is Proven 25-Year Technology Veteran
Mr. Helmer is an information technology executive with 25 years of experience and proven leadership delivering strategic corporate IT transformational projects. He has a strong track record in designing and implementing complex enterprise technology initiatives that provide organizations a real return on investment, competitive advantage and enable growth.
Prior to his appointment as CTO, Helmer led Rimini Street’s Strategic Services Group where he was responsible for the development and deployment of complex solutions for clients including advanced security, professional services, license management advisory, technical blueprints and cloud and migration services.
Before joining Rimini Street, Mr. Helmer was a vice president at Velocity Technology Solutions, where he led the application services team in delivering transformational cloud and IT solutions for Oracle enterprises. Additionally, he has a broad consulting background with firms such as Linium, ADI Strategies and The Hackett Group, where he has delivered many successful enterprise projects throughout the U.S., EMEA and APAC.
Mr. Helmer is a published author, Oracle ACE alumni and a sought-after, award-winning industry speaker at conferences and industry events. He also has served on many industry advisory boards, including the Oracle Developer Tools User Group (ODTUG). He holds a Master’s degree in business administration and a Bachelor of Science degree in computer science.
Current Enterprise Software as a Platform for Continuous Business Optimization
Most organizations only use a fraction of their current enterprise software system’s capabilities that they have licensed, paid for and are entitled to use. Often, organizations only leverage their ERP and other enterprise software minimally to run their basic business operations.
Rimini Street’s OCTO will work with clients to help them define best practices for both maximizing the return on their large, critical enterprise software investment and leverage their asset as a platform for continuous business optimization. The OCTO will take a holistic view of a prospect or client’s business to provide ongoing strategic advice to help improve the cost-benefit ratio of their software investment, align their software and technology roadmap to the business’ goals and help set the business or government entity up to leverage further innovation and drive growth or improved service levels. Through Rimini Street’s unique road-mapping services, a 360-degree advisory approach is taken to optimize existing platforms, including enhancing the system for functionality progression, cybersecurity hardening, technology futureproofing and cloud efficiencies.
“Organizations come to Rimini Street to gain the freedom from vendor-pressured upgrades and cloud migrations that lead to unnecessary disruption and excessive costs. Leading organizations want to follow their own business-driven roadmaps and smart paths to achieve their unique strategic IT, operational and financial goals,” said Helmer. “As leaders in enterprise software and technology, they look to Rimini Street to provide industry best practices for maximizing their current enterprise software investment through innovative and detailed roadmaps that help them create continuous value while simultaneously avoiding unnecessary, costly and disruptive software and system upgrades, migrations and projects that don’t improve competitive advantage or enable the growth or service improvements needed. I am excited to be taking on this role within the Company to deliver the highest value strategies, services and solutions to enterprise software licensees around the world.”
“We are pleased to appoint Eric to his new role as CTO, and excited to launch our new OCTO organization that will partner closely with our prospects and clients to solve real world issues and help them systematically optimize their existing enterprise software system and adjacent solutions, as well as helping them align with their organization’s goals,” said Seth A. Ravin , Rimini Street CEO. “The appointment of our CTO and the launch of the OCTO organization are major milestones as Rimini Street continues to lead the industry in redefining what award-winning enterprise software solutions look like and deliver to prospects and clients.”
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,200 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com , follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn .
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the impact of our credit facility’s ongoing debt service obligations and financial covenants and operational covenants on our business and related interest rate risk, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; including under our new credit facility; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 4, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005974/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
